216394-05-7

Usage

Uses

Used in Organic Synthesis:
5-Bromo-6-chloropyridine-3-sulfonyl chloride is used as a key intermediate for organic synthesis, facilitating the creation of a wide range of chemical compounds. Its unique structure allows for versatile reactions, making it a valuable component in the synthesis of various molecules.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 5-Bromo-6-chloropyridine-3-sulfonyl chloride is utilized as a crucial building block for the development of new drugs. Its incorporation into drug molecules can enhance their efficacy, selectivity, and pharmacological properties, contributing to the advancement of medicinal chemistry.
Used in Agrochemicals:
5-Bromo-6-chloropyridine-3-sulfonyl chloride is also employed in the agrochemical sector as an intermediate for the synthesis of various agrochemical products. Its use in this industry aids in the development of more effective and targeted pesticides, herbicides, and other agricultural chemicals.
Used in Dyestuff Field:
In the dyestuff field, 5-Bromo-6-chloropyridine-3-sulfonyl chloride is used as an intermediate for the production of dyes and pigments. Its chemical properties enable the creation of a diverse array of colorants, contributing to the vibrancy and variety of colors available in the market.
Overall, 5-Bromo-6-chloropyridine-3-sulfonyl chloride is a versatile and essential compound in multiple industries, playing a critical role in the development and synthesis of various products, from pharmaceuticals to dyes.

InChI:InChI=1/C5H2BrCl2NO2S/c6-4-1-3(12(8,10)11)2-9-5(4)7/h1-2H

Upstream product

• 16250-08-1 pyridine-2-amino-5-sulphonic acid 
• 504-29-0 2-aminopyridine 
• 247582-62-3 2-Amino-3-bromopyridine-5-sulphonic Acid 
• 109-01-3 1-methyl-piperazine 

Downstream Products

• 849349-02-6 5-bromo-N-[2-tert-butyl-1-(cyclohexylmethyl)-1H-benzimidazol-5-yl]-6-chloro-N-methylpyridine-3-sulfonamide 
• 247582-73-6 2-Ethoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridine-3-carboxylic Acid 
• 622815-22-9 C₈H₈BrClN₂O₂S 
• 1447647-67-7 C₁₁H₁₂BrClN₂O₂S 
• 1447647-68-8 C₁₂H₁₄BrClN₂O₂S 
• 1446235-26-2 4-[2-(2,4-difluorophenoxy)-5-(ethylsulfonyl)pyridin-3-yl]-6-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one 
• 1446237-24-6 4-(2-chloro-5-(ethylsulfonyl)pyridin-3-yl)-6-methyl-1-tosyl-1H-pyrrolo[2,3-c]pyridin-7(6H)-one 
• 1450621-14-3 2-amino-5-(((3S)-3-(1-propyn-1-yl)-4-(4-(2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl)phenyl)-1-piperazinyl)sulfonyl)-3-pyridinecarbonitrile 
• 1450621-11-0 3-bromo-5-(((3S)-3-(1-propyn-1-yl)-4-(4-(2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl)phenyl)-1-piperazinyl)sulfonyl)-2-pyridinol 
• 1450621-10-9 2-(4-((2S)-4-((6-amino-5-bromo-3-pyridinyl)sulfonyl)-2-(1-propyn-1-yl)-1-piperazinyl)phenyl)-1,1,1,3,3,3-hexafluoro-2-propanol 
• 1310475-05-8 trans-4-(5-bromo-6-chloro-pyridine-3-sulfonylamino)-cyclohexanecarboxylic acid [(R)-1-(4-fluoro-phenyl)-ethyl]-amide 
• 1357271-88-5 (1r,1r)-4-(1,3-dimethyl-1H-pyrrolo[2,3-b]pyridine-5-sulfonamido)-N-((R)-1-(4-fluorophenyl)ethyl)cyclohexanecarboxamide 
• 1357279-09-4 (1r,4r)-4-(6-(allyl(methyl)amino)-5-bromopyridine-3-sulfonamido)-N-((R)-1-(4-fluorophenyl)ethyl)cyclohexanecarboxamide 
• 1353433-10-9 4-(5-bromo-6-chloro-pyridine-3-sulfonylamino)-2-hydroxy-benzoic acid 

Relevant academic research and scientific papers

The discovery of UK-369003, a novel PDE5 inhibitor with the potential for oral bioavailability and dose-proportional pharmacokinetics

This paper describes our recent efforts to design and synthesise potent and selective PDE5 inhibitors and the use of in vitro predictors of clearance, absorption and permeability to maximise the potential for dose-proportional pharmacokinetics and good oral bioavailability in man. Optimisation of the preclinical profile resulted in the identification of UK-369003 (19a) and its nomination as a clinical candidate. The clinical pharmacokinetic and safety profile has enabled us to progress the compound to test its efficacy in patients with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) and a paper describing its efficacy has recently been published.2,3.

Discovery of potent, selective, and orally bioavailable alkynylphenoxyacetic acid CRTH2 (DP2) receptor antagonists for the treatment of allergic inflammatory diseases

New phenoxyacetic acid antagonists of CRTH2 are described. Following the discovery of a hit compound by a focused screening, high protein binding was identified as its main weakness. Optimization aimed at reducing serum protein binding led to the identification of several compounds that showed not only excellent affinities for the receptor (41 compounds with Ki 50 100 nM; PGD2-induced eosinophil shape change). Additional optimization of the PK characteristics led to the identification of several compounds suitable for in vivo testing. Of these, 19k and 19s were tested in two different pharmacological models (acute FITC-mediated contact hypersensitivity and ovalbumin-induced eosinophilia models) and found to be active after oral dosing (10 and 30 mg/kg).

PHENOXY ACETIC ACID DERIVATIVES

The present invention provides phenoxyacetic acid derivatives of Formula (I) for the treatment of CRTH2 related disorders and disease selected from asthma, atopic dermatitis and inflammatory dermatoses.

Treatment of neuropathy

This invention relates to the use of cyclic guanosine 3′,5′-monophosphate phosphodiesterase type five (cGMP PDE5) inhibitors, including in particular the compound sildenafil, for the treatment of neuropathy, including in particular the treatment of diabetic neuropathy.

Treatment of diabetic ulcers

This invention relates to the use of cyclic guanosine 3′, 5′-monophosphate phosphodiesterase type five (cGMP PDE5) inhibitors, including in particular the compound sildenafil, for the treatment of diabetic ulcers, particularly diabetic foot ulcers.

Treatments for female sexual dysfunction and methods for identifying compounds useful for treating female sexual dysfunction

The present invention provides a method of treating female sexual dysfunction, the method comprising the step of administering to a patent, having or at risk of having one or more of the disorders or conditions associated with female sexual dysfunction, a therapeutically effective amount of a compound that attenuates the binding of agouti-related protein to melanocortin receptors, but does not attenuate the binding of alpha-melanocyte stimulating hormone to melanocortin receptors. The present invention also provides a method of identifying a compound that is useful for the treatment or prevention of female sexual dysfunction, the method comprising the steps of: 1) determining if a compound affects the binding of agouti-related protein to melanocortin receptors; 2) determining if a compound affects the binding of alpha-melanocyte stimulating hormone to melanocortin receptors; and 3) selecting a compound that attenuates the binding of agouti-related protein to melanocortin receptors, but does not affect the binding of alpha-melanocyte stimulating hormone to melanocortin receptors.

Methods of treatment and kits comprising a growth hormone secretagogue

The present invention relates to methods of treating bulimia nervosa, male erectile dysfunction, female sexual dysfunction, thyroid cancer, breast cancer, or ameliorating ischemic nerve or muscle damage. The present invention also relates to kits that can be used in the treatment of bulimia nervosa, male erectile dysfunction, female sexual dysfunction, thyroid cancer, breast cancer, or ameliorating ischemic nerve or muscle damage. The present invention further relates to increasing gastrointestinal motility after surgery and increasing gastrointestinal motility in patients who have been administered an agent that decreases gastrointestinal motility.

Crystalline therapeutic agent

A polymorph of 1-{6-ethoxy-5-[3-ethyl-6,7-dihydro-2-(2-methoxyethyl)-7-oxo-2H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-pyridylsulfonyl}-4-ethylpiperazine.

Novel process for the preparation of pyrazolopyrimidinones

There is provided a process for the production a compound of general formula I: 1wherein A, R1, R2, R3 and R4 have meanings given in the description, which process comprises the dehydrogenation of a compound of general formula II, 2

Novel process for the preparation of pyrazolopyrimidinones

There is provided a process for the production a compound of general formula I: wherein A, R1, R2, R3 and R4 have meanings given in the description, which process comprises the reaction of a compound of formula II, wherein Rx is a group substitutable by an aminopyrazole, with a compound of general formula III